The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Moderna’s plans to manufacture commercial mRNA vaccines at its existing facility in Harwell in Oxfordshire.

Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement for Eli Lilly to acquire a manufacturing facility from Nexus.

Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with a new $5.3bn investment, increasing its investment at this site to $9bn from its original $3.7bn.

AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), with the aim of enhancing its global supply of its ADC portfolio.

Domainex has announced that it has opened a new biology centre of excellence at the Unity Campus at Pampisford, Cambridge, UK, in order to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and academic institutions.

BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in Africa, with the introduction of the new site in Kigali, Rwanda.

Prange Group and Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for their acquisition of its leading sterile pharmaceutical production site in Halden, Norway.

GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its metered-dose inhaler ventolin (salbutamol) using a next-generation propellant.

Novo Nordisk has announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, for production of the company’s current and future product portfolio within serious chronic diseases.

Merck has announced that it has invested €35m in biosafety testing at its sites in Glasgow and Stirling, both Scotland.

REGENXBIO, a clinical-stage biotech company, has announced positive phase 2 data for its drug rxg-314, which was developed by the company’s NAVXpress bioreactor platform process.

US biotech firm Moderna has chosen Harwell Science Campus in Oxfordshire for its new UK R&D facility. The campus is already home to more than 70 organisations and sits within the UK’s ‘golden triangle’, an area rich in life sciences facilities, between Oxford, Cambridge and London.